Table 4. Demographic, clinical, and laboratory data for patients with and without any hepatic fibrosis.
| Fibrosis | no Fibrosis | P-value | Test | |
| N | 32 | 5 | ||
| NASH | 22 (69%) | 0 (0%) | n/a | |
| Advanced fibrosis | 6 (19%) | 0 (0%) | n/a | |
| Diabetes | 10 (31%) | 3 (60%) | 0.321 | FE |
| Female | 23 (72%) | 2 (40%) | 0.304 | FE |
| Caucasian | 28 (88%) | 3 (60%) | 0.177 | FE |
| Age | 48±10 | 49±11 | 0.847 | 2T |
| BMI | 48±10 | 47±13 | 0.564 | MW |
| Hyperlipidemia | 19 (59%) | 4 (80%) | 0.630 | FE |
| Hypertension | 23 (72%) | 3 (60%) | 0.603 | FE |
| AST (U/L) | 22±6.4 | 22±10 | 0.956 | 2T |
| ALT (U/L) | 33±16 | 30±6.9 | 0.807 | MW |
| AST: ALT | 0.77±0.21 | 0.81±0.56 | 0.548 | MW |
| Albumin (g/dL) | 4.0±0.56 | 4.1±0.34 | 0.806 | MW |
| Bilirubin (total) (mg/dL) | 0.51±0.29 | 0.44±0.23 | 0.667 | MW |
| White blood cell count(103/uL) | 7.3±1.9 | 7.4±2.3 | 0.773 | MW |
| Platelet count (103/uL) | 267±72 | 306±79 | 0.347 | 2T |
| Hemoglobin (g/dL) | 14±1.3 | 13±1.3 | 0.299 | 2T |
| Glucose (mg/dL) | 112±41 | 103±17 | 0.947 | MW |
| Cholesterol (total) (mg/dL) | 191±34 | 170±35 | 0.267 | 2T |
| Triglycerides (mg/dL) | 182±126 | 142±87 | 0.351 | MW |
| HDL (mg/dL) | 48±8.9 | 51±16 | 0.667 | 2T |
| CCL-2 (pg/mL) | 457±138 | 570±279 | 0.374 | MW |
| sFasL (pg/mL) | 91±30 | 54±26 | 0.015 | MW |
| Portal fibrosis | 26 (81%) | 0 (0%) | n/a | |
| Pericellular fibrosis | 12 (38%) | 0 (0%) | n/a |
Entries are counts for discrete measures (with percentage of group total given in parentheses) or mean ± S.D. for continuous measures. A p-value of ≤0.05 was considered significant. Significant results are shown in bold text. FE = Fisher’s exact test; MW = Mann-Whitney U test; 2T = two-sample t-test (2-tailed).